← Back to Search

Neostigmine/Glycopyrrolate for Coronary Artery Disease

Phase 4
Waitlist Available
Research Sponsored by West Virginia University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18 - 70 years
American Society of Anesthesiology physical status I-4
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30-60 minutes post-extubation
Awards & highlights

Study Summary

This trial is testing if Sugammadex will help reduce time from anesthesia reversal to extubation, and improve other post-extubation outcomes, in patients who have had coronary artery bypass surgery.

Eligible Conditions
  • Coronary Artery Disease
  • Surgery

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30-60 minutes post-extubation
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30-60 minutes post-extubation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Time to Extubation
Secondary outcome measures
Blood Pressure (First Measurement of Systolic Blood Pressure Post Reversal)
Heart Rate
Peak Flow Rate
+2 more
Other outcome measures
Length of Stay Cardiac Intensive Care Unit
Occurrence of Postoperative Cardiac Complications
Occurrence of Postoperative Respiratory Complications
+3 more

Trial Design

2Treatment groups
Active Control
Group I: Neostigmine/GlycopyrrolateActive Control3 Interventions
Group 1: Intubation with rocuronium at 1.0-1.2 mg/kg (vitals maintained within 20% of baseline). Subjects may be re-dosed with rocuronium at 0.1-0.4 mg/kg during the procedure to maintain 1-2 twitches on train of four (TOF) watch monitor reading recorded every 15 minutes. Group 1 (control) will receive reversal with neostigmine (0.04-0.07 mg/kg up to 5 mg maximal dosage) and glycopyrrolate (0.07-0.015mg/kg up to 1 mg maximal dosage).
Group II: SugammadexActive Control2 Interventions
Group 2: Intubation with rocuronium at 1.0-1.2 mg/kg (vitals maintained within 20% of baseline). Subjects may be re-dosed with rocuronium at 0.1-0.4 mg/kg during the procedure to maintain 1-2 twitches on train of four (TOF) watch monitor reading recorded every 15 minutes. Group 2 (treatment) will receive reversal with Sugammadex (2mg/kg).

Find a Location

Who is running the clinical trial?

West Virginia UniversityLead Sponsor
174 Previous Clinical Trials
56,122 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
~14 spots leftby Mar 2025